The development of OTUD6B inhibitors thus seems warranted and we here present the biological and clinical framework and rationale from which to further approach this effort to improve the outcome of MM and potentially other tumors with an activated OTUD6B‐LIN28B axis. This evidence concerns the gene LIN28B and Miyoshi myopathy.